josti5 23 april 2009 11:16 auteur info josti5 Lid sinds: 23 feb 2005 Laatste bezoek: 16 jun 2024 Aanbevelingen Ontvangen: 16767 Gegeven: 20343 Aantal posts: 33.708 quote:aossa schreef:"Q1 2009 reported results include significant negative currency impact:"Wegens koers USD-CHF ?Hopelijk is het effect voor Crucell milder door wat strategische maatregelen op het currency vlak ... oa. financiering voorraad QV bmv geleende won's ipv in USD of CHF.De vorige keer viel dit item erg mee, negatief opgeklopt als het door sommigen op dit forum was. Aanbevelingen 1 ” Quote Reageren Niet oké
aossa 23 april 2009 11:26 auteur info aossa Lid sinds: 23 mei 2003 Laatste bezoek: 16 jun 2024 Aanbevelingen Ontvangen: 4041 Gegeven: 3338 Aantal posts: 17.606 En aangezien de voorraad QV in won wordt uitgedrukt, moet Novartis eveneens met won's tevreden zijn (Novartis deelt 50% mee in QV kosten en baten). Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 23 april 2009 12:08 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 whaw,ik heb dit maar even neergepend omdat ik er van overtuigd ben dat Novartis de partij is die Cru gaat overnemenwillemn op erik om 10.25 uureindelijk met je billen bloot! Aanbevelingen 0 ” Quote Reageren Niet oké
flosz 23 april 2009 12:35 auteur info flosz Lid sinds: 13 feb 2008 Laatste bezoek: 22 jun 2023 Aanbevelingen Ontvangen: 5298 Gegeven: 2795 Aantal posts: 7.005 quote:aossa schreef: (Novartis deelt 50% mee in QV kosten en baten).Novartis en Crucell verdelen de winst die op Quinvaxem gemaakt wordt. De precieze percentages zijn niet publiekelijk bekend gemaakt, wel kunnen wij zeggen: Novartis ietsje meer dan Crucell.(N.a.v. vraag maxen in juni 2007 via askthemanagement.nl) Aanbevelingen 0 ” Quote Reageren Niet oké
flosz 23 april 2009 12:35 auteur info flosz Lid sinds: 13 feb 2008 Laatste bezoek: 22 jun 2023 Aanbevelingen Ontvangen: 5298 Gegeven: 2795 Aantal posts: 7.005 quote:ruudje1 schreef:whaw,ik heb dit maar even neergepend omdat ik er van overtuigd ben dat Novartis de partij is die Cru gaat overnemenwillemn op erik om 10.25 uureindelijk met je billen bloot!willemn - 5 feb 09, 21:00www.iex.nl/forum/topic.asp?forum=228&...BTW er zijn er een heleboel die er zo over denken. Aanbevelingen 0 ” Quote Reageren Niet oké
aossa 23 april 2009 13:52 auteur info aossa Lid sinds: 23 mei 2003 Laatste bezoek: 16 jun 2024 Aanbevelingen Ontvangen: 4041 Gegeven: 3338 Aantal posts: 17.606 webcast 14:00services.choruscall.eu/products/strea...slides:services.choruscall.eu/dataconf/produ... Aanbevelingen 1 ” Quote Reageren Niet oké
[verwijderd] 13 juni 2009 10:14 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 www.businessweek.com/magazine/content...11 juni:Interview met CEO Novartis: even wachten tot de video gestart is.. Aanbevelingen 3 ” Quote Reageren Niet oké
flosz 13 juni 2009 12:11 auteur info flosz Lid sinds: 13 feb 2008 Laatste bezoek: 22 jun 2023 Aanbevelingen Ontvangen: 5298 Gegeven: 2795 Aantal posts: 7.005 Novartis: Radically Remaking Its Drug BusinessCEO Dan Vasella's growth mantra for Novartis is follow the science, not the financials Five neuroscientists file nervously into Novartis' (NVS) vast boardroom in Basel. CEO Daniel L. Vasella is seated at the table, along with nine senior executives that make up the company's innovation board. The scientists hope to persuade Vasella to move forward on an experimental vaccine for Alzheimer's disease, an illness that afflicts 25 million people worldwide. Even a moderately effective treatment would be a blockbuster, but testing the vaccine would take years and several hundred million dollars. When one of the scientists points out that other drugmakers are targeting the illness, Vasella just shakes his head. "We still don't know whether Alzheimer's is one disease or several, or if the current approaches even address the right disease mechanisms," he says, frustration edging into his voice. He sends the proposal back for a rethink. Vasella's ability to quickly set aside one of the world's most troubling diseases reflects a radical shift for Novartis—and one that may offer the drug industry its best chance to come up with the kinds of innovations that have eluded it for so long. Most big drugmakers shower their research and development funds on diseases such as cancer or depression, where huge potential markets beckon despite a deficit of scientific understanding. In recent years this approach has led to high rates of failure when drugs are tested in clinical trials. Seven years ago, Vasella, 55, took a calculated risk and turned Novartis' R&D model upside down. He resolved to push drugs through the long testing process only if they are backed by proven science. It doesn't matter whether the diseases the drugs treat are rare and the initial markets minuscule. Once a drug proves its worth against one disease, Vasella reasons, it can be tested against others. "If you are guided purely by financial estimates and not the science, you end up wasting time and money," he says. Vasella's goal is to institutionalize the lessons from one of the company's most successful creations, the cancer drug Gleevec. Initially approved for a rare blood cancer that strikes just a few thousand people each year, it has proven effective against six other life-threatening diseases. The drug pulled in $3.7 billion in revenues last year for Novartis, which posted a total of $9 billion in operating income on sales of $41.5 billion. Vasella admits Gleevec was something of a fluke: The drug has a complicated history that mostly predates Novartis' shift in strategy. Yet Gleevec's triumph helped crystallize Vasella's thinking. Today Novartis has 93 drug candidates in the pipeline, 40% more than three years ago, and 80% of Novartis' drugs last year made it from early testing to late-stage development. That's a 60% improvement over 2005. LOSING PATENTSIf Novartis can quickly build on this track record, it could mark a turning point for both the company and the industry. While plenty of biotech companies place a premium on science, for the past two decades most pharmaceutical companies have been more interested in developing and marketing blockbusters aimed at major diseases. In years past, this approach produced giant wins, including a host of famous cholesterol drugs as well as other moderately effective, mass-market medicines. But experts say drug companies have exhausted the easy targets. With patents on many older blockbusters starting to expire, the industry is poised to lose an estimated $140 billion in sales to generic competition over the next five years. Those revenue sources must be replaced. Despite multibillion-dollar research budgets, none of the top companies has a wealth of promising compounds in its development pipeline. The industry also faces regulators more vigilant than ever about safety, and health insurers starting to balk at covering costly drugs that bring only modest benefits.All these travails help explain the recent frenzy of drug-industry mergers and acquisitions, including the $68 billion union of Pfizer (PFE) and Wyeth (WYE) and the $41 billion marriage of Merck (MRK) and Schering-Plough. Yet the bigger these companies become, the fewer new drugs they seem to produce. U.S. pharmaceutical makers spent $65.2 billion on R&D in 2008, nearly double the tally in 2002, but only eight completely new or first-in-class drugs reached the market last year, half as many as in 2001. A former physician, Vasella reckons drug executives have strayed too far from their scientific roots and forgotten that their core customers are patients, not shareholders. "It's the tyranny of quarterly earnings," he says, a trace of an accent revealing his Swiss German upbringing. Vasella believes that focusing Novartis' research on smaller, narrowly defined groups of patients will lead to more targeted and effective therapies with fewer side effects. Regulators will therefore be inclined to approve them, and reimbursement will be less troublesome. "With so much waste in the health-care system, insurers cannot afford to bankroll me-too drugs," Dr. Lee N. Newcomer, senior vice-president for oncology at United Healthcare (UNH). "But if new approaches such as Novartis' mean the right patients will get the right drugs, insurers will likely pay for them." Vasella's vow to break with the status quo has won plaudits from management gurus who marvel at the inefficiencies in the drug sector. "He is not a prisoner of the existing paradigm. Instead, he is trying to change it," says Ram Charan, a leading consultant and author. "Vasella is able to anticipate and visualize radical change much the same way Steve Jobs did at Apple (AAPL), Andy Grove did at Intel (INTC), and Sam Walton did at Wal-Mart (WMT)." William W. George, professor of management practice at Harvard Business School and the former chairman and CEO of medical device maker Medtronic (MDT), says Vasella "has the mind of a long-term strategist." Some on Novartis' board were skeptical at first. "They kept asking: 'How will we know this huge investment will work?' " recalls George, who resigned from the board this past February when his son Jeff became head of Novartis' generics business, Sandoz. "Dan said: 'You won't know for at least a decade.' " The remark was vintage Vasella: confident, direct, and searingly honest. When I first met him nearly a decade ago, Novartis had stakes in both agribusiness and pharmaceuticals. Vasella believed gene-based sciences would soon prove the value of this union, but the synergies never materialized. Where hubris might have driven a less self-aware CEO to throw good money after bad, Vasella quickly ditched the seeds and chemicals business and focused on drugs. Aanbevelingen 1 ” Quote Reageren Niet oké
flosz 13 juni 2009 12:12 auteur info flosz Lid sinds: 13 feb 2008 Laatste bezoek: 22 jun 2023 Aanbevelingen Ontvangen: 5298 Gegeven: 2795 Aantal posts: 7.005 It was a natural decision, given Vasella's unusual status as a physician-CEO in a profession where nearly all top executives have backgrounds in law, accounting, or marketing. "The industry really needs more leaders who are as passionate as [he] is about the business. He is a CEO who thinks like a doctor," says George. Vasella's ability to keep patients in mind may come from his experiences not only as a physician but also as a patient. He described these to me in 2003 when we met to talk about Novartis' hopes for Gleevec. As a five-year-old growing up in the Swiss town of Fribourg, Vasella developed asthma and spent two summers on a farm in the mountains, separated from his family. At eight he contracted tuberculosis, followed by meningitis, and spent a year in a hospital and a sanatorium. But his greatest sorrows came later, starting when he was 10. "My older sister had Hodgkin's lymphoma," he told me. "I watched her over three years as she slowly got weaker. She died at 19." Three years later, his father died in surgery. A second sister, also a doctor, was killed in a car crash. Perhaps because of these tragedies, Vasella is devoted to his family. At the recent innovation board meeting, I was impressed when he unapologetically took a call from one of his three children. A GOOD LISTENERA childhood blighted by illness and loss led Vasella to a career in medicine. As a resident at the University of Bern, he worked with Dr. Rolf Adler, then head of internal medicine, who encouraged him to undergo psychoanalysis. It helped him work through his losses and sparked a lifelong interest in the field. (Vasella collects first-edition works of Sigmund Freud, among other authors.) Analysis also made Vasella a better doctor, says Adler, now professor emeritus at the University of Bern. "He was always question- ing both himself and others, but he was a good listener, too." Adler was disappointed when the young doctor decided to leave medicine for a career in business in 1988. The reasons were telling: Vasella was unwilling to wait out the years it would take in academia to be given a chance to lead. Moving to New Jersey, he took a position as a salesman for the Swiss drug company Sandoz, where his wife's uncle was chairman. In 1992 he returned to Switzerland to head marketing, and two years later he took over as CEO. In 1996, at the age of 43, he pulled off a merger between Sandoz and another mid-tier drugmaker, Ciba-Geigy, to form Novartis. Vasella's boldest move came in 2002, when he abandoned the traditional drug-development model. He declared that Novartis would investigate only diseases for which new drugs were desperately needed and where the genetics of the target illnesses were well understood. While other CEOs saw the pursuit of rare diseases as commercial suicide, Vasella believed many of the illnesses shared the genetic underpinnings with more common ailments. Vasella also decided to move Novartis' main global research operation from Basel to Cambridge, Mass., a short distance from MIT, Harvard, and other paragons of biological research. Vasella spent about $4 billion on the move and then quickly made another controversial decision: He recruited Dr. Mark C. Fishman, a renowned cardiologist from Harvard who had no industry experience, to run the center and overhaul Novartis' drug-discovery business. "When Dan first called, I thought he had the wrong number," says Fishman, whose work studying zebra fish resulted in the discovery of 100 genetic mutations involved in the cardiovascular system. Fishman was happy at Harvard and saw little reason to leave, but Vasella persevered. Fishman was the expert who convinced Vasella that medical research will reap the best results by focusing on a small number of important molecular pathways—the complex sequences of interactions among chemicals, proteins, and larger cell structures in the body that underlie all illnesses. "There are 24,000 genes in the genome, but there are only a few dozen pathways conserved throughout evolution," he says. With little known about how each gene functions in a larger cellular context, Fishman compares the genes to a mere list of words in a dictionary. Molecular pathways, he believes, are the missing grammar. Fishman reckons that finding all the links in a pathway and then locating the key signals that can turn genes on or off will lead Novartis to therapies for illnesses once deemed incurable: "The theory is, we will be able to apply them in disease after disease because the pathways are shared." While Fishman's new colleagues admired his knowledge of developmental biology, there were also hard feelings. Many Novartis scientists were struggling with the new management and the shift in power from Basel to Cambridge. "Some were angry and demotivated," Vasella concedes. "The changes bred a lot of insecurity." In particular, many questioned the choice of Fishman. "People in research wondered what value someone who had never led a research organization in the pharmaceutical industry brought," recalls James Shannon, chairman and CEO of San Francisco biotech Cerimon Pharmaceuticals and the former global head of development at Novartis. The biggest pushback came from the senior executives in sales and marketing who were used to calling the shots. Many couldn't fathom how a business model focused on small groups of patients would ever make money. The marketing side "was living happily off Diovan [Novartis' top-selling hypertension drug], only to have Mark Fishman tell them the age of the blockbuster is over," Shannon says. Things got worse when Fishman banned running commercial analyses of new drug candidates until the company had sufficient clinical data. This approach, backed by Vasella, was heresy in an industry that spends vast sums trying to assign a hypothetical value to each potential drug at every stage of the R&D process. "Dan threw a strategy on the table and said: 'This is it, go make it work,' " Shannon says. GAME-CHANGING TRIALThe most important test case for Vasella's ideas may turn out to be an illness almost nobody has heard of. It's an inflammatory disorder called Muckle-Wells syndrome in which a single genetic mutation results in the buildup of proteins that can cause rashes, joint pain, and fatal kidney damage. Muckle-Wells afflicts just a few thousand people worldwide, too small a number to attract most drugmakers. But Fishman and Vasella have a hunch the drug they've developed for it will prove effective in more widespread diseases. "With other companies, rare diseases are an afterthought," says Fishman. "For us they are often the starting point." The drug, a synthetic antibody that can tamp down out-of-control immune responses, isn't new. Novartis briefly tested it against arthritis, then abandoned it. In 2004 one of Fishman's scientists asked to retest it in a trial involving just four patients suffering from Muckle-Wells. Within 24 hours of receiving the medicine, all four showed dramatic improvement, and within a week the disease was barely detectable in the blood. Patients remained in remission for as long as six months. Aanbevelingen 1 ” Quote Reageren Niet oké
flosz 13 juni 2009 12:14 auteur info flosz Lid sinds: 13 feb 2008 Laatste bezoek: 22 jun 2023 Aanbevelingen Ontvangen: 5298 Gegeven: 2795 Aantal posts: 7.005 Despite these promising results, development efforts soon bogged down in debates over what the drug's exact commercial value might be. "This is precisely what paralyzes the industry and leads to the destruction of innovation," says Trevor Mundel, a physician-cum-mathematician brought in by Fishman as head of global development. The confusion persisted for a year and a half, Vasella recalls with irritation. The initial tests "took way too long, much longer than necessary." Vasella ultimately resolved the disputes, and Novartis went on to test its drug in several rare autoimmune ailments. Using advanced computer models to show how different patients might respond to the treatment, Novartis was able to persuade the Food & Drug Administration that it was safe to move directly to late-stage trials involving hundreds of patients with Muckle-Wells and a related cluster of immune system diseases, thus shaving a year off the expected development time and saving tens of millions of dollars. While Pfizer, GlaxoSmithKline (GSK), and others are also using simulation, "Novartis is far ahead of the rest of the industry," says Dr. Howard Lee, director of the Center for Drug Development Science in Washington. Vasella places a high premium on medical experience. After a major restructuring in 2007 that led to the loss of 1,260 sales and marketing jobs, Vasella replaced some of the company's senior leaders with medically trained scientists who grasped his approach. According to Shannon, some of the old guard fled voluntarily. "They saw Daniel rewarding projects such as Muckle-Wells and said: 'If this is what the future of the company looks like, it's not for us,' " he explains. On June 3, The New England Journal of Medicine published important data on Novartis' phase 3 trial of the Muckle-Wells drug, now called Ilaris. More than 90% of children and adults suffering from the immune disorders the drug was designed to treat had rapid and sustained remissions. The drug is under priority review with the FDA, and Novartis hopes to seek approval for use against a variety of autoimmune diseases, including Type 2 diabetes and severe arthritis. There is much more in the pipeline. Novartis is neck-and-neck in a race with Germany's Merck to launch the first oral treatment for multiple sclerosis. And Novartis' drug Afinitor, approved by the FDA in March for advanced kidney cancer, shows promise in six other forms of the disease. In trial data released this month, Afinitor shrank tumors by 50% or more in one-third of patients suffering from lymphoma, a cancer of the lymph system. And Gleevec? Fresh evidence shows that it targets the same genetic mutation involved in certain forms of melanoma, the deadliest of skin cancers. The lesson, says Fishman: "Well-designed drugs just keep on giving." ****************Novartis chief bets big on science-based discovery modelJune 12, 2009 — 8:11am ET | By John Carroll BusinessWeek casts Novartis CEO Daniel Vasella (photo) as a champion of science bucking the current trend of big mergers in favor of an ambitious investment in experimental drugs in a major piece exploring the drug giant's discovery model.Vasella's main point is one that has become a well-worn mantra among all the big pharma companies: Truly innovative first-in-class therapies will be needed to replace all those big blockbusters losing patent protection in the next few years. Me-too drugs are out. But instead of acquiring promising new companies, Vasella has been betting that the company's pipeline--built on a better understanding of the genetic triggers that cause disease--can produce dramatic new advances in pharmaceuticals.As proof, BusinessWeek offers up some numbers. Eighty percent of the company's drugs made it from early-stage to late-stage testing, which is 60 percent better than the company's record in 2005. And there are now 93 drugs in the pipeline, 40 percent more than three years ago.The way Vasella presents it, Novartis is all about good science. If the science is there and the program can deliver, the company is all for it. Forget any pesky little details like potential market size. "If you are guided purely by financial estimates and not the science, you end up wasting time and money," he says.The profile pulls out all the stops in canonizing Vasella, the sickly child who grew up to become a physican and later helm a major drug company. And it's hard to swallow the assertion that market potential hardly registers in the pipeline equation at Novartis. But he is making a concerted effort to show that big pharma can actually produce important new drugs on its own.www.fiercebiotech.com/story/novartis-... Aanbevelingen 1 ” Quote Reageren Niet oké
flosz 26 juni 2009 14:26 auteur info flosz Lid sinds: 13 feb 2008 Laatste bezoek: 22 jun 2023 Aanbevelingen Ontvangen: 5298 Gegeven: 2795 Aantal posts: 7.005 Ixiaro (vaccin tegen Japanse encefalitis) Lisätietoja tästä lääkevalmisteesta antaa myyntiluvan haltijan paikallinen edustaja:Voor meer informatie over dit product geeft de houder van een vertegenwoordiger van de lokale..Crucell: Denemarken, Noorwegen, Finland en Zweden.www.emea.europa.eu/humandocs/PDFs/EPA... Aanbevelingen 2 ” Quote Reageren Niet oké
flosz 28 juni 2009 11:14 auteur info flosz Lid sinds: 13 feb 2008 Laatste bezoek: 22 jun 2023 Aanbevelingen Ontvangen: 5298 Gegeven: 2795 Aantal posts: 7.005 Novartis -> 15,3% IntercellNovartis markets and distributes Intercell’s JE vaccine under the trade name IXIARO in the U.S. and Europe and holds commercialization rights for Japan, Korea, and certain defined markets in Latin America and Asia. CSL Biotherapies is Intercell’s marketing and distribution partner in Australia, New Zealand, Papua New Guinea, and the Pacific Islands, where the product is marketed as JESPECTR. Biological E. Ltd. will manufacture and market the product in India, Bhutan, Nepal, and Bangladesh.Furthermore, Intercell’s JE vaccine has shown a successful ability to prevent childhood Japanese Encephalitis.Analysis of Phase II data suggests that a half-dose given to young children (1 to 3 years of age) has the excellent immunogenicity and the safety profile comparable to that of adults taking the full dosage.The start of Phase III clinical trials for the pediatric vaccine in India is planned for 2009.2008 was in many ways dedicated to bringing Intercell’s first vaccine to the market.The Company proved its expertise in the development, production, and commercialization of a product.The JE vaccine acts as a front runner for further products to enter the global markets.www.intercell.com/uploads/media/2008_...P.40.www.intercell.com/fileadmin/user_uplo...(Iomai Corporation=Intercell)Btw: Goldman Sucks loves Intercell.www.intercell.com/uploads/media/2008-...Zo ook Berenberg Bank, uit sep., 2008:The peer group is not meaningfulBelow is the comparison of peer group multiples but just for informativepurposes. The reason: there is no real peer group for Intercell due to itsunique positioning:- Early phase of earnings – with no current product in the market, Intercellcannot be compared to established large vaccine players which are alsoactive in the drug business which is less favourable in terms ofcompetition and growth.- The product pipeline is significantly larger than that of other youngbiotech companies, thus a comparison is not justified here either.www.intercell.com/uploads/media/2008-...P.15 Aanbevelingen 0 ” Quote Reageren Niet oké
pardon 10 december 2009 23:36 auteur info pardon Lid sinds: 19 jan 2004 Laatste bezoek: 12 sep 2022 Aanbevelingen Ontvangen: 1387 Gegeven: 2812 Aantal posts: 16.824 Free Newsletter Free Weekly FierceVaccines Update: About | View Sample | Privacy Related Topics >> Aeras Global TB Vaccine Foundation | Tuberculosis Vaccine | TuberculosisResearchers target first new TB vax in decadesDecember 10, 2009 — 10:51am ET | By John Carroll Related StoriesSanofi licenses technology for new TB vaccineCrucell reports early-stage success with TB vaccineResearchers develop recombinant TB vaxScientists successful in early-stage TB vax trialAeras Global unveils new TB vax facilityTools EmailPrintCommentContact AuthorReprintAfter years of inattention, health officials are preparing an ambitious set of field trials for the first new tuberculosis vaccine since 1920. And health officials in Uganda, where the vaccine will be tested in two of the country's districts, say fresh advances are badly needed."New TB drugs and vaccines will be important[;] they will change the lives of ordinary people. It is definitely important to have a new vaccine," said Anne Wajja, the country's head of TB vaccine studies. Only one TB vaccine exists, reports Reuters. The Bacille Calmette-Guerin shot was developed in 1920, and with the exception of rifabutin, there has been no new drug for TB in more than 40 years.Ann Ginsberg, chief medical officer of the TB Alliance, said that "there is renewed attention to the problem, and awakening and rebuilding again after many years of lying fallow. It was only in the 80s and 90s when TB resurged in the west and north that everyone woke up and the U.S. Congress asked 'this (TB) exists?' New York City had to spend $1 billion in 1990 just to get the TB epidemic in New York City under control."Progress on a new vaccine now could eliminate the disease. "We think that eventually we could prevent enough people from having the disease and acquiring (the bacteria) that the transmission rate will be so low that the disease will go away," said Jerald Sadoff, president of the Aeras Global TB Vaccine Foundation.- here's the story from ReutersRead more: www.fiercevaccines.com/story/research... Aanbevelingen 0 ” Quote Reageren Niet oké
pardon 10 december 2009 23:38 auteur info pardon Lid sinds: 19 jan 2004 Laatste bezoek: 12 sep 2022 Aanbevelingen Ontvangen: 1387 Gegeven: 2812 Aantal posts: 16.824 Crucell reports early-stage success with TB vaccineApril 10, 2008 — 6:59am ET Related StoriesAeras Global unveils new TB vax facilityScientists successful in early-stage TB vax trialResearchers develop recombinant TB vaxSanofi licenses technology for new TB vaccineCrucell gains key support for malaria vaccine programTools EmailPrintCommentContact AuthorReprintShares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. The Dutch biotech is teamed up with the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative in advancing AERAS-402/Crucell Ad35. And a third early-stage vaccine trial is underway in South Africa, which has an extraordinarily high rate of the disease. The currently used vaccine, Bacille Calmette-Guerin, was developed 85 years ago, but is regarded as largely ineffective against pulmonary TB. "While preliminary, these results are promising. We are pleased that Crucell's technologies are playing a key role in the search and development of a much-needed TB vaccine," said Dr. Jaap Goudsmit, chief scientific officer at Crucell. "We highly value the collaboration with Aeras and SATVI on this important mission." - see the release- read this report Related Articles:In surprise move, Crucell dumps West Nile programCrucell, MedImmune strike dealCrucell acquires SBL Vaccin for €39.4M. Report Read more: www.fiercevaccines.com/story/crucell-... Aanbevelingen 0 ” Quote Reageren Niet oké
pardon 10 december 2009 23:40 auteur info pardon Lid sinds: 19 jan 2004 Laatste bezoek: 12 sep 2022 Aanbevelingen Ontvangen: 1387 Gegeven: 2812 Aantal posts: 16.824 Related Topics >> Vaccine | PATH Malaria Vaccine Initiative | Malaria | CrucellCrucell gains key support for malaria vaccine programJuly 30, 2009 — 10:05am ET | By John Carroll Related StoriesNew collaboration aims at next-gen malaria vaccineMalaria trials will pay volunteers to get infectedGSK begins phase III global trial for malaria vaxSanaria starts adult trial of malaria vax PATH finds cheap method to guard vax stocksTools EmailPrintCommentContact AuthorReprintThe Dutch biotech Crucell has picked up financial support for its malaria vaccine program through a newly inked collaboration with the PATH Malaria Vaccine Initiative and USAID's Malaria Vaccine Development Program.Crucell didn't disclose just how much it is getting, but the money will finance work on two technologies that may help defeat the malaria parasite. Crucell's AdVac technology is used to load viral genetic material into a drug delivery vehicle--the adenovirus serotypes Ad35 and Ad26--while the PER.C6 gene tech platform is used to produce vaccine"This agreement is a strong validation of Crucell's malaria vaccine approach," Crucell's chief scientific officer, Jaap Goudsmit, said in a statement."Adenoviruses are one of the most potent vaccine delivery systems tested to date in humans. We are excited about the potential of Crucell's adenovirus-based program and the novel Ad35/Ad26 approach. The prime-boost regimen may be a critical next step in malaria vaccine development and, if successful, could move us toward our goal of having an 80 percent efficacious vaccine in use by 2025," said MVI Director, Dr. Christian Loucq.- read the press release- read the report from ReutersALSO: Researchers have focused on a number of new technologies to defeat malaria. In one case, scientists used mosquitoes to effectively deliver a vaccine. "Malaria vaccines are moving from the laboratory into the real world," Dr. Carlos Campbell wrote in an editorial accompanying the study in Thursday's New England Journal of Medicine. ReportRead more: www.fiercevaccines.com/story/crucell-... Aanbevelingen 0 ” Quote Reageren Niet oké
pardon 10 december 2009 23:44 auteur info pardon Lid sinds: 19 jan 2004 Laatste bezoek: 12 sep 2022 Aanbevelingen Ontvangen: 1387 Gegeven: 2812 Aantal posts: 16.824 Ik heb even 3 berichten geplaatst waarom plaatst crucell die berichten niet!! Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 11 december 2009 07:47 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:pardon schreef:Ik heb even 3 berichten geplaatst waarom plaatst crucell die berichten niet!!Klooster??, waar een spreekverbod geld voor 364 dagen per jaar!1 dag , wel mogen praten per jaar , om het niet te verleren (:->D) !? Aanbevelingen 0 ” Quote Reageren Niet oké
maxen 11 december 2009 08:28 auteur info maxen Lid sinds: 17 sep 2003 Laatste bezoek: 13 sep 2022 Aanbevelingen Ontvangen: 3604 Gegeven: 1214 Aantal posts: 2.488 quote:pardon schreef:Ik heb even 3 berichten geplaatst waarom plaatst crucell die berichten niet!![/quote]Zoals 1 van je berichten al aangeeft:[quote=pardon]Crucell reports early-stage success....HEEFT Crucell die berichten al geplaatst, tot 1 1/2 jaar geleden. Dus je loopt enigszins achter, Pardon.Lijkt me niet nodig voor Crucell om berichten te gaan herhalen.Los daarvan doe je aan draadjesvervuiling, want deze berichten hebben niets met Novartis van doen. Aanbevelingen 3 ” Quote Reageren Niet oké
[verwijderd] 11 december 2009 08:48 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 hihi, zo graag willen wij nieuws vanuit het klooster horen.Beter een herhaling dan helemaal GEEN nieuws :>))) Aanbevelingen 0 ” Quote Reageren Niet oké
flosz 11 december 2009 12:40 auteur info flosz Lid sinds: 13 feb 2008 Laatste bezoek: 22 jun 2023 Aanbevelingen Ontvangen: 5298 Gegeven: 2795 Aantal posts: 7.005 quote:pardon schreef:Ik heb even 3 berichten geplaatst waarom plaatst crucell die berichten niet!!www.geleidehond.nl/geleidehond_voor_u_ Aanbevelingen 3 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.